Floatz
- Company typePrivate
- Founded2024
- HeadquartersDover, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Floatz firmographics
Firmographics- Name
- Floatz
- Website
- https://floatz.ai
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Floatz industry classification
Industry- Product category
- Life-Science Investment Due Diligence Software
- NAICS
- Portfolio Management and Investment Advice (523940), Other Scientific and Technical Consulting Services (54169), Scientific Research and Development Services (5417)
- SIC
- Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Transaction Analytics & Cash-Flow Insights (risk signals, forecasting) (FSAGACAG)
Keywords
Where Floatz is headquartered
LocationHeadquarters
- HQ city
- Dover
- HQ country
- United States
- HQ region
- North America
Markets served
Floatz business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Floatz product offering
Product offeringCore offering
Floatz provides an AI-powered platform that enables life-science investors to conduct scientific due diligence on potential biotech and healthcare investments. The platform analyzes research data, scientific literature, and related evidence to systematically evaluate the science behind investment targets. It is targeted at venture capital firms, private equity, and institutional investors focused on biotech, pharma, and healthcare sectors.
Product overview
Floatz provides an AI-driven platform for scientific due diligence targeting life-science investors. The company offers a single unified product focused on analyzing and evaluating scientific data and research for investment decision-making purposes.
Differentiator
Problem solved
Functional benefit
Products and services
- Floatz AI-powered platform that enables life-science investors, including venture capital firms, private equity, and institutional investors focused on biotech, pharma, and healthcare, to conduct scientific due diligence on potential investments by analyzing research data, scientific literature, and related evidence to inform investment decisions.
Companies that use Floatz
Customer profileSegments1 record
Ideal customer profiles1 record
Floatz technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Floatz partnerships and signals
Strategic signalRecent moves2 records
Floatz competitors and assessment
Company assessmentDirect peers
- AlphaSense: Market intelligence and search platform widely used by investment professionals to analyze research, filings, and expert transcripts. Comparable to Floatz as an AI-driven tool that supports investor due-diligence workflows, though it operates across all sectors rather than specializing in life sciences.
- CB Insights: Market intelligence platform focused on private-company and technology data, used heavily by VCs and corporate strategists. Comparable to Floatz as a data and analytics platform supporting investment decision-making, with strong coverage of biotech and healthcare.
- Tegus: Research platform for investment professionals offering expert transcripts and primary-source diligence content. Comparable to Floatz as an AI-enhanced diligence workflow tool for investors, though Tegus emphasizes expert calls over scientific-literature analysis.
Broad incumbents
- PitchBook: Comprehensive private-markets data platform used by PE and VC firms for deal sourcing, due diligence, and market analysis. Comparable as investor-facing data infrastructure that Floatz would complement or compete against for life-science deal evaluation.
- S&P Capital IQ Pro: Broad financial intelligence platform covering public and private companies for investment professionals. Comparable to Floatz as an investor-workflow data platform with deep coverage, including life sciences, but operating across all sectors.
- Informa Pharma Intelligence (Citeline): Pharma and biotech intelligence suite covering clinical trials, pipelines, deals, and company profiles. Comparable to Floatz as a life-science–specific intelligence provider, but with established incumbent depth in trial and regulatory data.
- Source Bioscience / Evaluate (now Norstella): Evaluate provides commercial intelligence and forecasting for the pharma and biotech industry, widely used by investors. Comparable to Floatz as a quantitative, data-driven intelligence layer supporting life-science investment and corporate strategy decisions.
Regional players
- BioCentury: Long-standing biotech industry intelligence and analysis provider serving investors and biopharma executives. Comparable to Floatz as a scientific-analysis resource for life-science investors, though delivered primarily through editorial content rather than AI tooling.
Emerging players
- DealForma: Biotech deal database and analytics platform for licensing, M&A, and financing transactions. Comparable to Floatz as a specialized life-science deal intelligence tool used by biotech investors and business-development teams.
- Biomedtracker: Drug-development pipeline and clinical-trial analytics platform for investors and biopharma. Comparable to Floatz as a life-science–specific analytics tool used by investors to assess scientific and clinical risk in investment decisions.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Floatz social profiles
Digital presenceFloatz financial estimates
Financial estimateRevenue estimate
Valuation estimate
Floatz leadership team
Management profileNumber of profiles
Floatz funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Floatz M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Floatz
What does Floatz do?
Floatz provides an AI-powered platform that enables life-science investors to conduct scientific due diligence on potential biotech and healthcare investments. The platform analyzes research data, scientific literature, and related evidence to systematically evaluate the science behind investment targets. It is targeted at venture capital firms, private equity, and institutional investors focused on biotech, pharma, and healthcare sectors.
When was Floatz founded?
Floatz was founded in 2024. It employs 1 to 10 people.
Where is Floatz based?
Floatz is headquartered in Dover, United States, in the North America region.
Who are Floatz's main competitors?
Direct peers on record are AlphaSense, CB Insights and Tegus. Broad incumbents are PitchBook, S&P Capital IQ Pro, Informa Pharma Intelligence (Citeline) and Source Bioscience / Evaluate (now Norstella). BioCentury is listed as a regional player. Emerging players are DealForma and Biomedtracker.
Does Floatz have an API?
No public API is recorded for Floatz.
What industry is Floatz in?
Floatz's product category is Life-Science Investment Due Diligence Software. Its primary akta.pro industry code is FSAGACAG, Transaction Analytics & Cash-Flow Insights (risk signals, forecasting). Its NAICS code is 523940 and its SIC code is 6282.